4,329 Shares in Cencora, Inc. (NYSE:COR) Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,329 shares of the company’s stock, valued at approximately $974,000.

Other institutional investors have also added to or reduced their stakes in the company. Boston Partners bought a new position in shares of Cencora during the 1st quarter valued at approximately $1,001,269,000. Pacer Advisors Inc. lifted its position in Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock valued at $464,874,000 after purchasing an additional 2,035,679 shares during the last quarter. Legal & General Group Plc lifted its position in Cencora by 3.7% during the second quarter. Legal & General Group Plc now owns 1,875,445 shares of the company’s stock valued at $422,538,000 after purchasing an additional 67,287 shares during the last quarter. Swedbank AB grew its stake in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after buying an additional 31,104 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Cencora by 10.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,262,882 shares of the company’s stock worth $284,544,000 after buying an additional 119,927 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.5 %

NYSE:COR opened at $249.70 on Thursday. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $251.56. The stock has a market capitalization of $49.20 billion, a price-to-earnings ratio of 33.08, a PEG ratio of 1.63 and a beta of 0.44. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a 50 day moving average of $233.56 and a 200 day moving average of $232.01.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. Cencora’s dividend payout ratio is presently 29.29%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders sold 93,018 shares of company stock worth $22,478,942 in the last 90 days. Insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on COR shares. JPMorgan Chase & Co. lifted their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company upped their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Evercore ISI upped their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, Bank of America reiterated a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.